ATIC基因多态性与非小细胞肺癌培美曲塞疗效及毒性相关
这项前瞻性多中心队列研究在晚期非小细胞肺癌患者中,探讨了培美曲塞代谢通路相关9个候选基因的10个多态性与疗效及毒性的关联。校正性别、ECOG评分和疾病分期后,ATIC rs12995526与总生存显著相关(HR 1.59,95%CI 1.06-2.39),且与严重实验室毒性、临床毒性、严重中性粒细胞减少及全等级腹泻显著相关。
要点
- ATIC rs12995526与培美曲塞治疗晚期NSCLC的总生存显著相关。
- 该多态性还与严重实验室和临床化疗不良事件、严重中性粒细胞减少及全等级腹泻相关。
- 研究覆盖叶酸通路、细胞转运、胞内代谢及靶酶相关基因的多态性。
核心结论
- ATIC rs12995526与培美曲塞治疗晚期非小细胞肺癌的总生存及多项毒性终点显著相关。
研究设计与样本
- 前瞻性多中心队列研究,纳入接受培美曲塞治疗的晚期非小细胞肺癌患者,检测9个候选基因的10个多态性。
主要发现
- 校正性别、ECOG评分和疾病分期后,ATIC rs12995526与总生存显著相关(HR 1.59,95%CI 1.06-2.39)。
- 多因素分析显示该多态性与严重实验室化疗不良事件(p=0.014)和严重临床化疗不良事件(p=0.016)显著相关。
- 该多态性还与严重中性粒细胞减少(p=0.007)及全等级腹泻(p=0.034)显著相关。
关键数值与推荐
- ATIC rs12995526与总生存关联的HR为1.59(95%CI 1.06-2.39)。
- 严重实验室毒性p=0.014,严重临床毒性p=0.016,严重中性粒细胞减少p=0.007,全等级腹泻p=0.034。
临床怎么用
- ATIC rs12995526或可作为接受培美曲塞治疗的晚期非小细胞肺癌患者疗效与毒性风险的候选遗传标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with advanced non-small-cell lung cancer who are treated with pemetrexed display a wide variation in clinical response and toxicity. In this prospective, multicentre cohort study, we investigated the association with treatment effectiveness and toxicity of 10 polymorphisms in nine candidate genes, covering the folate pathway (MTHFR), cell transport (SLC19A1/ABCC2/ABCC4), intracellular metabolism (FPGS/GGH) and target enzymes (TYMS/DHFR/ATIC) of pemetrexed. Adjusted for sex, ECOG performance score and disease stage, the association between ATIC (rs12995526) and overall survival (HR 1.59, 95% CI 1.06 to 2.39) was significant. Regarding toxicity, this ATIC polymorphism was significantly associated with severe laboratory (p=0.014) and clinical (p=0.016) chemotherapy-related adverse events, severe neutropenia (p=0.007) and all-grade diarrhoea (p=0.034) in multivariable analyses.
引用
- Visser S, Koolen S, van Donk N, et al. Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer. Thorax. 2021. PMID: 33859051. doi:10.1136/thoraxjnl-2020-216504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。